-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) announced that in May 2026, the holding subsidiary Fosun Pharmaceutical Industry signed an “Exclusive Option Agreement” with AriBio. (This mainly includes) Fosun Pharmaceutical Industry was granted and enjoyed new licensing regions around the world (including core markets such as the United States, Europe, Japan, etc.) and licensing fields (that is, for the diagnosis, prevention and treatment of all types of Alzheimer's disease) licensed products (that is, using the AR1001 molecule as its active ingredient the exclusive right of choice of drug) rights.
Share
Listen to the news
Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) announced that in May 2026, the holding subsidiary Fosun Pharmaceutical Industry signed an “Exclusive Option Agreement” with AriBio. (This mainly includes) Fosun Pharmaceutical Industry was granted and enjoyed new licensing regions around the world (including core markets such as the United States, Europe, Japan, etc.) and licensing fields (that is, for the diagnosis, prevention and treatment of all types of Alzheimer's disease) licensed products (that is, using the AR1001 molecule as its active ingredient <whether or not the only active ingredient) > the exclusive right of choice of drug) rights.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending